CERPASS: A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination with RP1 in Patients with Advanced Cutaneous Squamous Cell Carcinoma.

  • Haydon, Andrew (Primary Chief Investigator (PCI))
  • Hawkins, Cheryl-Ann (Project Manager)

Project: Research

Project Details

StatusFinished
Effective start/end date12/12/19 → 31/12/25

Keywords

  • Medical Oncology
  • Squamous cell carcinoma
  • Clinical trial

Clinical Trial Phase

  • Phase II